Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) — The “U.S. Cancer Biopsy Market Size, Share & Trends Analysis by Type, Cause, and Site, 2025-2030” report has been added to ResearchAndMarkets.com’s offering.
The U.S. cancer biopsy market size is expected to reach USD 20.18 billion by 2030, registering a CAGR of 10.8% from 2025 to 2030. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.
The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.
Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.
Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.
Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.
Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.
U.S. Cancer Biopsy Market Report Highlights
- The fine-needle aspiration segment dominated the market with the largest revenue share of 32.2% in 2024, driven by the increasing prevalence of cancer and a growing preference for minimally invasive procedures.
- The screening & monitoring segment dominated the market with the largest revenue share in 2024, attributable to the rising demand for regular health check-ups and early cancer detection.
- The breast segment held a significant share of the market in 2024, driven by the rising incidence of breast cancer. As one of the most diagnosed cancers among women, breast cancer needs frequent diagnostic assessment, including biopsies, to determine the presence and stage of the disease.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Key Attributes
| Report Attribute | Details |
| No. of Pages | 80 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $10.83 billion |
| Forecasted Market Value (USD) by 2030 | $20.18 billion |
| Compound Annual Growth Rate | 10.8% |
| Regions Covered | United States |
Key Topics Covered
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Cancer Biopsy Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis – Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
Chapter 4. U.S. Cancer Biopsy Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
4.4. Fine-needle Aspiration
4.5. Core Biopsy
4.6. Surgical Biopsy
4.7. Skin Biopsy /Punch Biopsy
4.8. Others
Chapter 5. U.S. Cancer Biopsy Market: Cause (Application) Business Analysis
5.1. Cause (Application) Market Share, 2024 & 2030
5.2. Cause (Application) Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Cause (Application), 2018 to 2030 (USD Billion)
5.4. Screening & Monitoring
5.5. Diagnostics
5.6. Investigational & Translational Research
5.7. Pharma & Biopharma Discovery & Development
Chapter 6. U.S. Cancer Biopsy Market: Site (Organ) Business Analysis
6.1. Site (Organ) Market Share, 2024 & 2030
6.2. Site (Organ) Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Site (Organ), 2018 to 2030 (USD Billion)
6.4. Liver
6.5. Breast
6.6. Thyroid
6.7. Prostate Gland
6.8. Uterus & Cervix
6.9. Kidney
6.10. Bladder
6.11. Lungs
6.12. Pancreas
6.13. Others
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. BD (Becton, Dickinson and Company)
7.5.2. IZI Medical Products
7.5.3. Johnson & Johnson Services, Inc.
7.5.4. Argon Medical Devices
7.5.5. SPECTRA MEDICAL DEVICES, LLC
7.5.6. Medtronic
7.5.7. Boston Scientific Corporation
7.5.8. CONMED Corporation
7.5.9. INRAD, Inc.
7.5.10. Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/dgjzb6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- U.S. Cancer Biopsy Market
